Literature DB >> 24475862

Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid--enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation.

Na Yeon Han1, Beom Jin Park, Deuk Jae Sung, Min Ju Kim, Sung Bum Cho, Chang Hee Lee, Yun-Jin Jang, So Yeon Kim, Dong Sik Kim, Soon Ho Um, Nam Hee Won, Kyung Sook Yang.   

Abstract

PURPOSE: To retrospectively evaluate findings of chemotherapy-induced focal hepatopathy (CIFH) on gadoxetic acid-enhanced magnetic resonance (MR) and diffusion-weighted (DW) images and to determine imaging features that are most helpful in differentiating CIFH from metastasis.
MATERIALS AND METHODS: This retrospective study was approved by the institutional review board, and informed consent was waived. MR images, including DW images and gadoxetic acid-enhanced images, from 12 patients (four men, eight women; age range, 25-64 years) with 15 CIFHs were reviewed independently and in consensus by two radiologists and were compared with those obtained in 20 control patients (12 men, eight women; age range, 32-84 years) with 30 hepatic metastasis who were matched for tumor size, primary organ, and chemotherapy regimen. Interobserver agreement was assessed with κ statistics, and univariate analysis was performed for comparisons. For quantitative analyses, apparent diffusion coefficients (ADCs) and lesion-to-liver contrast ratios (CRs) were measured. Histopathologic examinations were performed for CIFHs.
RESULTS: Histopathologic examination revealed that the development of CIFHs was attributable to accentuated manifestations of sinusoidal obstruction syndrome. Interobserver agreement was excellent (κ > 0.85). An ill-defined margin on hepatobiliary phase (HBP) images was the most discriminating independent variable in the differentiation of CIFH from metastasis (odds ratio, 16; P = .009). ADC and CR values in CIFH group were significantly higher than those in metastasis group (P < .001 and P = .041).
CONCLUSION: CIFH should be considered a mimicker of metastasis in patients with gastrointestinal malignancy during chemotherapy. CIFH can be differentiated from metastasis on the basis of gadoxetic acid-enhanced MR and DW imaging findings; an ill-defined margin on HBP images was especially characteristic.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24475862     DOI: 10.1148/radiol.13131810

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  17 in total

Review 1.  Imaging strategies in the management of gastric cancer: current role and future potential of MRI.

Authors:  Alicia S Borggreve; Lucas Goense; Hylke J F Brenkman; Stella Mook; Gert J Meijer; Frank J Wessels; Marcel Verheij; Edwin P M Jansen; Richard van Hillegersberg; Peter S N van Rossum; Jelle P Ruurda
Journal:  Br J Radiol       Date:  2019-03-05       Impact factor: 3.039

Review 2.  Joint Consensus Statement of the Indian National Association for Study of the Liver and Indian Radiological and Imaging Association for the Diagnosis and Imaging of Hepatocellular Carcinoma Incorporating Liver Imaging Reporting and Data System.

Authors:  Sonal Krishan; Radha K Dhiman; Navin Kalra; Raju Sharma; Sanjay S Baijal; Anil Arora; Ajay Gulati; Anu Eapan; Ashish Verma; Shyam Keshava; Amar Mukund; S Deva; Ravi Chaudhary; Karthick Ganesan; Sunil Taneja; Ujjwal Gorsi; Shivanand Gamanagatti; Kumble S Madhusudan; Pankaj Puri; Shallini Govil; Manav Wadhavan; Sanjiv Saigal; Ashish Kumar; Shallini Thapar; Ajay Duseja; Neeraj Saraf; Anubhav Khandelwal; Sumit Mukhopadyay; Ajay Gulati; Nitin Shetty; Nipun Verma
Journal:  J Clin Exp Hepatol       Date:  2019-08-06

3.  Gadoxetic acid-enhanced MRI and diffusion-weighted imaging for the detection of colorectal liver metastases after neoadjuvant chemotherapy.

Authors:  Mi Hye Yu; Jeong Min Lee; Bo Yun Hur; Tae-You Kim; Seung-Yong Jeong; Nam-Joon Yi; Kyung-Suk Suh; Joon Koo Han; Byung-Ihn Choi
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

4.  Oxaliplatin-induced hepatic sinusoidal obstruction syndrome in a patient with gastric cancer: A case report.

Authors:  Fang Liu; Xin Cao; Jin Ye; Xiaoli Pan; Xuefeng Kan; Yuhu Song
Journal:  Mol Clin Oncol       Date:  2017-12-18

Review 5.  Chemotherapy-Induced Liver Injury in Patients with Colorectal Liver Metastases: Findings from MR Imaging.

Authors:  Francescamaria Donati; Dania Cioni; Salvatore Guarino; Maria Letizia Mazzeo; Emanuele Neri; Piero Boraschi
Journal:  Diagnostics (Basel)       Date:  2022-03-31

6.  Predicting liver metastasis of gastrointestinal tract cancer by diffusion-weighted imaging of apparent diffusion coefficient values.

Authors:  De-Xian Zheng; Shu-Chun Meng; Qing-Jun Liu; Chuan-Ting Li; Xi-Dan Shang; Yu-Seng Zhu; Tian-Jun Bai; Shi-Ming Xu
Journal:  World J Gastroenterol       Date:  2016-03-14       Impact factor: 5.742

7.  ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.

Authors:  E Neri; M A Bali; A Ba-Ssalamah; P Boraschi; G Brancatelli; F Caseiro Alves; L Grazioli; T Helmberger; J M Lee; R Manfredi; L Martì-Bonmatì; C Matos; E M Merkle; B Op De Beeck; W Schima; S Skehan; V Vilgrain; C Zech; C Bartolozzi
Journal:  Eur Radiol       Date:  2015-07-21       Impact factor: 5.315

Review 8.  Imaging of HCC-Current State of the Art.

Authors:  Christina Schraml; Sascha Kaufmann; Hansjoerg Rempp; Roland Syha; Dominik Ketelsen; Mike Notohamiprodjo; Konstantin Nikolaou
Journal:  Diagnostics (Basel)       Date:  2015-11-27

9.  Diagnostic performance of Contrast-enhanced CT in Pyrrolizidine Alkaloids-induced Hepatic Sinusoidal Obstructive Syndrome.

Authors:  Xuefeng Kan; Jin Ye; Xinxin Rong; Zhiwen Lu; Xin Li; Yong Wang; Ling Yang; Keshu Xu; Yuhu Song; Xiaohua Hou
Journal:  Sci Rep       Date:  2016-11-29       Impact factor: 4.379

10.  FOLFOX and capecitabine-induced hepatic granuloma mimicking metastasis in a rectal cancer patient.

Authors:  Vinu Sarathy; Rajesh Kumar Kothandath Shankar; Suhail Sayeed Mufti; Radheshyam Naik
Journal:  BMJ Case Rep       Date:  2020-03-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.